Skip to main content
Premium Trial:

Request an Annual Quote

DiaCarta Raises $8M in Series A Round

NEW YORK (GenomeWeb) – DiaCarta today announced it raised $8 million in a Series A financing round. 

Proceeds will go toward commercialization of its products and the expansion of its portfolio, it said, adding the financing came from BioVeda China Fund. In conjunction with BVCF's financing, Weixin Xu, a principal at the venture capital fund, will join DiaCarta's board.

Based in Hayward, Calif., DiaCarta calls itself a translational genomics and molecular diagnostics firm that has CE-IVD assays for detecting EGFR, KRAS, NRAS, BRAF, PIK3CA, and JAK-2 mutations. Its QClamp mutation detection assays use a novel xeno-nucleic acid clamping technology to suppress amplification of wild-type DNA, enabling researchers to selectively amplify mutant DNA with real-time PCR.

According to the company, the technology can detect mutant DNA present at less than .1 percent, and its sensitivity and specificity make QClamp superior to next-generation sequencing and droplet digital PCR.

In addition to CE-IVD marking, its assays have been cleared by the Chinese Food and Drug Administration, DiaCarta said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.